Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis

Cancer Cell(2021)10.1016/j.ccell.2021.07.006Source: DataRank Database

Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis is a research paper published in Cancer Cell (2021). On theSindex it has a DataRank of 0. It has been cited 174 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access174 citations

Download PDF

Cite:

Linked data & code

cellosaurus

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (17 grants)Impact (FWCI 11.41)OA: greenTopics (48)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (20)

Helena A. Yu ORCID,Shaoyuan Yang,Song Han ORCID,S. Duygu Selçuklu ORCID,Kwanghee Kim ORCID

Live enrichment

PubMed:34388376 PMC:PMC8440494 OpenAlex:https://openalex.org/W3190172544

National Cancer Institute

Grant: P30CA008748

National Cancer Institute

Grant: R01CA125562

National Cancer Institute

Grant: R01CA252658

NCI NIH HHS

Grant: R00 CA207871

Sanofi Genzyme

AstraZeneca

Exelixis

Merck

American Lung Association

Novartis

Daiichi-Sankyo

National Institutes of Health

Bristol-Myers Squibb

Janssen Pharmaceuticals

Japan Society for the Promotion of Science

Pfizer

AbbVie

FWCI

11.41

Citation Percentile

1.0%

Citation Trend

2022

2023

2024

2025

2026

greenLicense: http://www.elsevier.com/open-access/userlicense/1.0/

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8440494

publisherhttps://api.elsevier.com/content/article/PII:S1535610821003834?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1535610821003834?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.ccell.2021.07.006

Fields of Study

Microtubule and mitosis dynamicsCancer-related Molecular PathwaysProtein Degradation and Inhibitors

MeSH Terms

Bcl-2-Like Protein 11AcrylamidesAniline CompoundsCarcinoma, Non-Small-Cell LungDrug Screening Assays, AntitumorDrug SynergismHumansIndolesLung NeoplasmsProto-Oncogene ProteinsPyrimidinesGene Expression Regulation, NeoplasticDrug Resistance, NeoplasmCell Line, TumorProtein Kinase InhibitorsApoptosis Regulatory ProteinsSmall Molecule LibrariesHigh-Throughput Screening AssaysEpithelial-Mesenchymal TransitionAurora Kinase B

Keywords

PumaAurora inhibitorCancer researchKinaseMitotic catastropheAurora kinaseApoptosisLung cancerCancer cellOsimertinibAurora A kinaseCancerBiologyEpidermal growth factor receptorMedicineCell biologyCell cycleErlotinibOncologyDrug resistanceDrug toleranceBcl-2 familyEmtAurora B KinaseLineage Plasticity

Sustainable Development Goals

SDG 0: Good health and well-being

Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis

FAIR Checklist

Authors (20)

Funding (17 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)